{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:34:13Z","timestamp":1789475653405,"version":"build-2803163510"},"update-to":[{"DOI":"10.1002\/14651858.cd005027.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2019,7,16]],"date-time":"2019-07-16T00:00:00Z","timestamp":1563235200000}}],"reference-count":77,"publisher":"Wiley","issue":"7","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd005027.pub5","type":"journal-article","created":{"date-parts":[[2019,7,16]],"date-time":"2019-07-16T08:28:40Z","timestamp":1563265720000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Interventions for morphea"],"prefix":"10.1002","volume":"2019","author":[{"given":"Julia V de","family":"Albuquerque","sequence":"first","affiliation":[{"name":"Cochrane Brazil, Centro de Estudos de Sa\u00fade Baseada em Evid\u00eancias e Avalia\u00e7\u00e3o Tecnol\u00f3gica em Sa\u00fade; Rua Borges Lagoa, 564 cj 63 S\u00e3o Paulo S\u00e3o Paulo Brazil 04038-000"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda NG","family":"Andriolo","sequence":"additional","affiliation":[{"name":"Centro de Estudos de Sa\u00fade Baseada em Evid\u00eancias e Avalia\u00e7\u00e3o Tecnol\u00f3gica em Sa\u00fade; Cochrane Brazil; Rua Borges Lagoa, 564 cj 63 S\u00e3o Paulo S\u00e3o Paulo Brazil 04038-000"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica RA","family":"Vasconcellos","sequence":"additional","affiliation":[{"name":"Universidade Federal de S\u00e3o Paulo; Department of Dermatology; Pedro de Toledo St. 508 S\u00e3o Paulo Brazil 04039-001"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinicius T","family":"Civile","sequence":"additional","affiliation":[{"name":"Centro de Estudos de Sa\u00fade Baseada em Evid\u00eancias e Avalia\u00e7\u00e3o Tecnol\u00f3gica em Sa\u00fade; Cochrane Brazil; Rua Borges Lagoa, 564 cj 63 S\u00e3o Paulo S\u00e3o Paulo Brazil 04038-000"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Lyddiatt","sequence":"additional","affiliation":[{"name":"The University of Nottingham; c\/o Cochrane Skin Group; A103, King's Meadow Campus Lenton Lane Nottingham UK NG7 2NR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia FM","family":"Trevisani","sequence":"additional","affiliation":[{"name":"Centro de Estudos de Sa\u00fade Baseada em Evid\u00eancias e Avalia\u00e7\u00e3o Tecnol\u00f3gica em Sa\u00fade; Cochrane Brazil; Rua Borges Lagoa, 564 cj 63 S\u00e3o Paulo S\u00e3o Paulo Brazil 04038-000"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,7,16]]},"reference":[{"issue":"3","key":"10.1002\/14651858.CD005027.pub5-BIB0001|cit1","first-page":"60","article-title":"Comparison of hydroxychloroquine and methotrexate in treatment of patients with localized scleroderma","volume":"35","author":"Azimi","year":"2013","journal-title":"Medical Journal of the Egyptian Armed Forces"},{"issue":"5","key":"10.1002\/14651858.CD005027.pub5-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/j.1365-2230.2008.02873.x","article-title":"Photodynamic therapy for the treatment of morphoea","volume":"33","author":"Batchelor","year":"2008","journal-title":"Clinical and Experimental Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD005027.pub5-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1600-0781.2004.00081.x","article-title":"Different low doses of broad-band UVA in the treatment of morphea and systemic sclerosis","volume":"20","author":"El-Mofty","year":"2004","journal-title":"Photodermatology, Photoimmunology & Photomedicine"},{"issue":"6","key":"10.1002\/14651858.CD005027.pub5-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1365-2230.2012.04385.x","article-title":"Subcutaneous administration of polymerized type I collagen downregulates interleukin (IL)-17A, IL-22 and transforming growth factor-beta1 expression, and increases Foxp3-expressing cells in localized scleroderma","volume":"37","author":"Furuzawa-Carballeda","year":"2012","journal-title":"Clinical and Experimental Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD005027.pub5-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1067\/mjd.2000.108369","article-title":"Double-blind, placebo-controlled study of oral calcitriol for the treatment of localized and systemic scleroderma","volume":"43","author":"Hulshof","year":"2000","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3 Pt 1","key":"10.1002\/14651858.CD005027.pub5-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0190-9622(97)80221-6","article-title":"Double-blind, placebo-controlled study of intralesional interferon gamma for the treatment of localized scleroderma","volume":"36","author":"Hunzelmann","year":"1997","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD005027.pub5-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jaad.2005.11.1063","article-title":"A randomized controlled study of low-dose UVA1, medium-dose UVA1, and narrowband UVB phototherapy in the treatment of localized scleroderma","volume":"54","author":"Kreuter","year":"2006","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD005027.pub5-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2165\/00128071-200910030-00004","article-title":"Efficacy of topical tacrolimus 0.1 in active plaque morphea: Randomized, double-blind, emollient-controlled pilot study","volume":"10","author":"Kroft","year":"2009","journal-title":"American Journal of Clinical Dermatology"},{"key":"10.1002\/14651858.CD005027.pub5-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2147\/CCID.S160923","article-title":"Assessing the response of morphea and limited scleroderma to tranilast: a small prospective study comparing topical corticosteroids to a combination of topical corticosteroids and tranilast","volume":"11","author":"Noakes","year":"2018","journal-title":"Clinical, Cosmetic and Investigational Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD005027.pub5-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.jaad.2008.12.013","article-title":"Medium-dose is more effective than low-dose ultraviolet A1 phototherapy for localized scleroderma as shown by 20-MHz ultrasound assessment","volume":"60","author":"Sator","year":"2009","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"8","key":"10.1002\/14651858.CD005027.pub5-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1007\/s10103-016-2041-5","article-title":"Fractional carbon dioxide laser versus low-dose UVA-1 phototherapy for treatment of localized scleroderma: a clinical and immunohistochemical randomized controlled study","volume":"31","author":"Shalaby","year":"2016","journal-title":"Lasers in Medical Science"},{"issue":"3","key":"10.1002\/14651858.CD005027.pub5-BIB0012|cit12","first-page":"100","article-title":"Treatment of localized scleroderma with herbs of traditional chinese medicine","volume":"27","author":"Tang","year":"2006","journal-title":"Kosmetische Medizin"},{"issue":"5","key":"10.1002\/14651858.CD005027.pub5-BIB0013|cit13","first-page":"403","article-title":"Efficacy observation on acupuncture and moxibustion combined with hot compress of TCM herbs for scleroderma","volume":"33","author":"Yan","year":"2013","journal-title":"Zhongguo Zhen Jiu [Chinese Acupuncture & Moxibustion]"},{"issue":"7","key":"10.1002\/14651858.CD005027.pub5-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/art.30264","article-title":"Methotrexate treatment in juvenile localized scleroderma: a randomized, double-blind, placebo-controlled trial","volume":"63","author":"Zulian","year":"2011","journal-title":"Arthritis and Rheumatism"},{"issue":"10","key":"10.1002\/14651858.CD005027.pub5-BIB0015|cit15","first-page":"725","article-title":"Localized scleroderma in childhood and therapeutic trial with calcitriol: A therapeutic option to define","volume":"126","author":"Bodemer","year":"1999","journal-title":"Annales de Dermatologie et de Venereologie"},{"key":"10.1002\/14651858.CD005027.pub5-BIB0016|cit16","first-page":"76","article-title":"Therapeutic effectiveness of ultrasonics and lidase phonophoresis in various forms of scleroderma","volume":"6","author":"Didenko","year":"1978","journal-title":"Vestnik Dermatologii i Venerologii"},{"issue":"3","key":"10.1002\/14651858.CD005027.pub5-BIB0017|cit17","first-page":"381","article-title":"Evaluation of Elarzone-Dausse phlebology","volume":"27","author":"Dortu","year":"1974","journal-title":"Phlebologie"},{"issue":"2","key":"10.1002\/14651858.CD005027.pub5-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2310\/7750.2014.14072","article-title":"Evaluation of the efficacy and safety of topical imiquimod 5% for plaque-type morphea: a multicenter, prospective, vehicle-controlled trial","volume":"19","author":"Dytoc","year":"2015","journal-title":"Journal of Cutaneous Medicine & Surgery"},{"issue":"4","key":"10.1002\/14651858.CD005027.pub5-BIB0019|cit19","first-page":"284","article-title":"Clinical observation on the efficacy of Prostaglandin E1 and Propylene glycol alginate sodium in the treatment of scleroderma","volume":"29","author":"Hu","year":"1996","journal-title":"Chinese journal of dermatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005027.pub5-BIB0020|cit20","first-page":"S273","article-title":"Gonadotherapy as a treatment of patients with localized scleroderma","volume":"11","author":"Smirnov","journal-title":"Journal of the European Academy of Dermatology & Venereology"},{"key":"10.1002\/14651858.CD005027.pub5-BIB0021|cit21","unstructured":"UVA1 Light for Treatment of Scleroderma and Similar Conditions clinicaltrials.gov\/ct2\/show\/NCT00476801"},{"issue":"7","key":"10.1002\/14651858.CD005027.pub5-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/archderm.144.7.851","article-title":"Effect of increased pigmentation on the antifibrotic response of human skin to UV-A1 phototherapy","volume":"144","author":"Wang","year":"2008","journal-title":"Archives of dermatology"},{"key":"10.1002\/14651858.CD005027.pub5-BIB0023|cit23","unstructured":"NCT00812188 A prospective, open label trial of high dose UVA-1, 3x\/week or medium dose UVA-1, 3x\/week vs. fluocinonide 0.05% cream treatment of morphea clinicaltrials.gov\/ct2\/show\/record\/NCT00812188"},{"key":"10.1002\/14651858.CD005027.pub5-BIB0024|cit24","unstructured":"NCT01799174 Treatment study comparing UVA-1 phototherapy versus placebo treatment for morphea clinicaltrials.gov\/ct2\/show\/NCT01799174"},{"issue":"2","key":"10.1002\/14651858.CD005027.pub5-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/rheumatology\/kep361","article-title":"Development and initial validation of the Localized Scleroderma Skin Damage Index and Physician Global Assessment of disease Damage: a proof-of-concept study","volume":"49","author":"Arkachaisri","year":"2010","journal-title":"Rheumatology"},{"issue":"7","key":"10.1002\/14651858.CD005027.pub5-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/1346-8138.14161","article-title":"Diagnostic criteria, severity classification and guidelines of localized scleroderma","volume":"45","author":"Asano","year":"2018","journal-title":"Journal of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD005027.pub5-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/rheumatology\/ken405","article-title":"Pathogenesis and therapeutic approaches for improved topical treatment in localized scleroderma and systemic sclerosis","volume":"48","author":"Badea","year":"2009","journal-title":"Rheumatology"},{"issue":"2","key":"10.1002\/14651858.CD005027.pub5-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/BOR.0b013e32834ff2e8","article-title":"Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers","volume":"24","author":"Barnes","year":"2012","journal-title":"Current Opinion in Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD005027.pub5-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/BOR.0b013e3283524b9a","article-title":"Innovative antifibrotic therapies in systemic sclerosis","volume":"24","author":"Beyer","year":"2012","journal-title":"Current Opinion in Rheumatology"},{"issue":"8","key":"10.1002\/14651858.CD005027.pub5-BIB0030|cit30","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.ad.2012.10.003","article-title":"Update on the classification and treatment of localized scleroderma","volume":"104","author":"Bielsa Marsol","year":"2013","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas"},{"issue":"1","key":"10.1002\/14651858.CD005027.pub5-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1590\/abd1806-4841.20152890","article-title":"Localized scleroderma: clinical spectrum and therapeutic update","volume":"90","author":"Careta","year":"2015","journal-title":"Anais Brasileiros de Dermatologia"},{"issue":"1","key":"10.1002\/14651858.CD005027.pub5-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1440-0960.2003.06301.x","article-title":"Epidemiology and pathogenesis of scleroderma","volume":"44","author":"Chen","year":"2003","journal-title":"Australasian Journal of Dermatology"},{"issue":"7","key":"10.1002\/14651858.CD005027.pub5-BIB0033|cit33","first-page":"1281","article-title":"Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis","volume":"22","author":"Clements","year":"1995","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD005027.pub5-BIB0034|cit34","unstructured":"Cochrane Skin - Core Outcome Set Initiative cs-cousin.org\/ (accessed 04 March 2019)"},{"issue":"4","key":"10.1002\/14651858.CD005027.pub5-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/j.1365-2133.2005.06776.x","article-title":"First case series on the use of imiquimod for morphoea","volume":"153","author":"Dytoc","year":"2005","journal-title":"British Journal of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD005027.pub5-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jaad.2010.05.045","article-title":"Update on morphea. Part I. Epidemiology, clinical presentation, and pathogenesis","volume":"64","author":"Fett","year":"2011","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD005027.pub5-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jaad.2010.05.046","article-title":"Update on morphea. Part II. Outcome measures and treatment","volume":"64","author":"Fett","year":"2011","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD005027.pub5-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"135","DOI":"10.4103\/0378-6323.93628","article-title":"Morphea: Evidence-based recommendations for treatment","volume":"78","author":"Fett","year":"2012","journal-title":"Indian Journal of Dermatology, Venereology and Leprology"},{"key":"10.1002\/14651858.CD005027.pub5-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.clindermatol.2013.01.010","article-title":"Scleroderma: nomenclature, etiology, pathogenesis, prognosis, and treatments: facts and controversies","volume":"31.4","author":"Fett","year":"2013","journal-title":"Clinics in dermatology"},{"key":"10.1002\/14651858.CD005027.pub5-BIB0040|cit40","unstructured":"Sch\u00fcnemann H Bro\u017cek J Guyatt G Oxman A editor(s) Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013 Available from gdt.guidelinedevelopment.org\/app\/handbook\/handbook.html"},{"key":"10.1002\/14651858.CD005027.pub5-BIB0041|cit41","unstructured":"McMaster University (developed by Evidence Prime) GRADEpro GDT 2015"},{"issue":"8","key":"10.1002\/14651858.CD005027.pub5-BIB0042|cit42","first-page":"754","article-title":"Treatment of scleroderma","volume":"134","author":"Guillevin","year":"1983","journal-title":"Annals of Internal Medicine"},{"issue":"2","key":"10.1002\/14651858.CD005027.pub5-BIB0043|cit43","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000956","article-title":"Prazosin for Raynaud\u2019s phenomenon in progressive systemic sclerosis","author":"Harding","year":"1998","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD005027.pub5-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1053\/sder.2001.23093","article-title":"Localized and systemic scleroderma","volume":"20","author":"Hawk","year":"2001","journal-title":"Seminars in Cutaneous Medicine and Surgery"},{"key":"10.1002\/14651858.CD005027.pub5-BIB0045|cit45","unstructured":"Higgins JP Green S editor(s) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"1","key":"10.1002\/14651858.CD005027.pub5-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S1085-5629(98)80060-6","article-title":"Management of localized scleroderma","volume":"17","author":"Hunzelmann","year":"March 1998","journal-title":"Seminars in Cutaneous Medicine & Surgery"},{"issue":"5","key":"10.1002\/14651858.CD005027.pub5-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.jaad.2012.01.011","article-title":"Morphea in adults and children cohort II: Patients with morphea experience delay in diagnosis and large variation in treatment","volume":"67","author":"Johnson","year":"November 2012","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD005027.pub5-BIB0048|cit48","first-page":"367","article-title":"A modified scleroderma skin scoring method","volume":"4","author":"Kahaleh","year":"1985","journal-title":"Clinical and Experimental Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD005027.pub5-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0002-9343(89)80150-0","article-title":"Recombinant interferon-\u03b3 in the treatment of systemic sclerosis","volume":"87","author":"Kahan","year":"1989","journal-title":"American Journal of Medicine"},{"key":"10.1002\/14651858.CD005027.pub5-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/jdv.14458","article-title":"European Dermatology Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes","volume":"31(9)","author":"Knobler","year":"2017","journal-title":"Journal of the European Academy of Dermatology and Venereology : JEADV"},{"issue":"3","key":"10.1002\/14651858.CD005027.pub5-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/bjd.13596","article-title":"Recurrence rates in localized scleroderma (morphoea)","volume":"172","author":"Kreuter","year":"2015","journal-title":"British Journal of Dermatology"},{"issue":"9","key":"10.1002\/14651858.CD005027.pub5-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1001\/archdermatol.2009.202","article-title":"Psychological distress in patients with morphea and eosinophilic fasciitis","volume":"145","author":"Kroft","year":"2009","journal-title":"Archives of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD005027.pub5-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1097\/01.bor.0000245727.40630.c3","article-title":"Localized scleroderma","volume":"18","author":"Laxer","year":"2006","journal-title":"Current Opinion in Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD005027.pub5-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3109\/14764172.2012.738910","article-title":"Non-ablative 1540 fractional laser: how far could it help injection lipolysis and dermal fillers in lower-face rejuvenation? A randomized controlled trial","volume":"15","author":"Leheta","year":"2013","journal-title":"Journal of Cosmetic and Laser Therapy"},{"issue":"5","key":"10.1002\/14651858.CD005027.pub5-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1001\/archdermatol.2009.79","article-title":"Distinct autoimmune syndromes in morphea: a review of 245 adult and pediatric cases","volume":"145","author":"Leitenberger","year":"2009","journal-title":"Archives of Dermatology"},{"issue":"8","key":"10.1002\/14651858.CD005027.pub5-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/acr.21687","article-title":"Development of consensus treatment plans for juvenile localized scleroderma: a roadmap toward comparative effectiveness studies in juvenile localized scleroderma","volume":"64","author":"Li","year":"2012","journal-title":"Arthritis Care & Research"},{"issue":"8","key":"10.1002\/14651858.CD005027.pub5-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.ad.2012.10.003","article-title":"Update on the classification and treatment of localized scleroderma","volume":"104","author":"Bielsa Marsol","year":"2013","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas"},{"issue":"1","key":"10.1002\/14651858.CD005027.pub5-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S1085-5629(98)80058-8","article-title":"Classification and epidemiology of scleroderma","volume":"17","author":"Mayes","year":"1998","journal-title":"Seminars in cutaneous medicine and surgery"},{"issue":"3","key":"10.1002\/14651858.CD005027.pub5-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/bjd.13514","article-title":"Disease recurrence in localized scleroderma: a retrospective analysis of 344 patients with paediatric-or adult-onset disease","volume":"172","author":"Mertens","year":"2015","journal-title":"British Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD005027.pub5-BIB0060|cit60","first-page":"73","article-title":"The epidemiology of morphea (localized scleroderma) in Olmsted County 1960-1993","volume":"4","author":"Peterson","year":"1997","journal-title":"The Journal of rheumatology"},{"issue":"2","key":"10.1002\/14651858.CD005027.pub5-BIB0061|cit61","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000954","article-title":"Ketanserin for Raynaud\u2019s phenomenon in progressive systemic sclerosis","author":"Pope","year":"1998","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD005027.pub5-BIB0062|cit62","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000953","article-title":"Iloprost and cisaprost for Raynaud\u2019s phenomenon in progressive systemic sclerosis","author":"Pope","year":"1998","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD005027.pub5-BIB0063|cit63","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5) 2014"},{"key":"10.1002\/14651858.CD005027.pub5-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"73.1","DOI":"10.1002\/9781444317633.ch75","article-title":"73. Drug Reactions","volume-title":"Rook's Textbook of Dermatology","volume":"4","author":"Breathnach","year":"2010"},{"issue":"4 Suppl 23","key":"10.1002\/14651858.CD005027.pub5-BIB0065|cit65","first-page":"S91","article-title":"The Italian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ)","volume":"19","author":"Ruperto","year":"2001","journal-title":"Clinical and Experimental Rheumatology"},{"issue":"9","key":"10.1002\/14651858.CD005027.pub5-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1001\/archdermatol.2010.239","article-title":"An evaluation of long-term outcomes in adults with pediatric-onset morphea","volume":"146","author":"Saxton-Daniels","year":"2010","journal-title":"Archives of Dermatology"},{"key":"10.1002\/14651858.CD005027.pub5-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"c332","DOI":"10.1136\/bmj.c332","article-title":"CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Schulz","year":"2010","journal-title":"BMJ"},{"issue":"5","key":"10.1002\/14651858.CD005027.pub5-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"652","DOI":"10.7326\/0003-4819-97-5-652","article-title":"D-Penicillamine therapy in progressive systemic sclerosis (scleroderma)","volume":"97","author":"Steen","year":"1982","journal-title":"Annals of Internal Medicine"},{"issue":"2","key":"10.1002\/14651858.CD005027.pub5-BIB0069|cit69","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000955","article-title":"Cyclofenil for Raynaud\u2019s phenomenon in progressive systemic sclerosis","author":"Tingey","year":"1998","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD005027.pub5-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"86","DOI":"10.2174\/1573397112666160907105434","article-title":"Localized scleroderma: a clinical review","volume":"13","author":"Tratenberg","year":"2017","journal-title":"Current Rheumatology Reviews"},{"issue":"10","key":"10.1002\/14651858.CD005027.pub5-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3390\/medicina46100092","article-title":"Pathogenesis and treatment modalities of localized scleroderma","volume":"46","author":"Valanciene","year":"2010","journal-title":"Medicina (Kaunas, Lithuania)"},{"issue":"6","key":"10.1002\/14651858.CD005027.pub5-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/BOR.0b013e32835896ce","article-title":"Morphea and other localized forms of scleroderma","volume":"24","author":"Vasquez","year":"2012","journal-title":"Current Opinion in Rheumatology"},{"issue":"10","key":"10.1002\/14651858.CD005027.pub5-BIB0073|cit73","first-page":"1213","article-title":"Treatment of morphea or localized scleroderma: review of the literature","volume":"9","author":"Vilela","year":"2010","journal-title":"Journal of Drugs in Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD005027.pub5-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"444","DOI":"10.2340\/0001555574444446","article-title":"Skin scoring in systemic sclerosis: a modification-relations to subtypes and the aminoterminalpropeptide of type III procollagen (PIIINP)","volume":"74","author":"Zachariae","year":"1994","journal-title":"Acta Dermato-venereologica"},{"issue":"1","key":"10.1002\/14651858.CD005027.pub5-BIB0075|cit75","first-page":"1","article-title":"UVA1 phototherapy: a concise and practical review","volume":"17","author":"Zandi","year":"2012","journal-title":"Skin Therapy Letter"},{"issue":"5","key":"10.1002\/14651858.CD005027.pub5-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.jaad.2010.09.006","article-title":"A systematic review of morphea treatments and therapeutic algorithm","volume":"65","author":"Zwischenberger","year":"2011","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD005027.pub5-BIB0077|cit77","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005027.pub4","article-title":"Interventions for morphea","author":"Ravelli","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD005027.pub5\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,21]],"date-time":"2024-07-21T00:21:37Z","timestamp":1721521297000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD005027.pub5"}},"subtitle":[],"editor":[{"name":"Cochrane Skin Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,7,16]]},"references-count":77,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019,7]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd005027.pub5","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,16]]}}}